Precision Immunotherapy™
investors-relations
Home/Investor Relations/Press Releases
Investor Relations

Quick Links

Email Alerts

Email Address *
Mailing Lists *




 
Enter the code shown above.

Press Releases

2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
12/23/2013 Opexa Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
12/17/2013 Opexa Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
12/17/2013 Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
12/16/2013 Opexa Therapeutics Provides MS Trial Enrollment Update; 70% of Patients Enrolled
11/12/2021 Opexa Therapeutics Selected as a “Top 10 Advanced Therapy Projects to Watch”
11/08/2022 Opexa CEO Invited to Join Personalized Medicine Panel at New York CEO Conference
11/07/2022 Opexa Therapeutics Reports Third Quarter 2013 Financial Results and Provides Corporate Update
11/06/2022 Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Third Quarter 2013 Financial Results
10/23/2013 Opexa Therapeutics Supports National Multiple Sclerosis Society as a Corporate Sponsor of Walk MS
10/21/2013 Opexa Therapeutics Immune Monitoring Program Featured in Neurology Reviews
10/17/2013 Opexa Therapeutics CEO to Appear on The RedChip Money Report on Fox Business News
10/07/2022 Opexa Therapeutics’ CEO Featured in Leading Life Science Publication
10/02/2022 Opexa Therapeutics’ Therapy for Multiple Sclerosis Featured in FOX Television News Story
09/30/2013 Opexa CEO Invited Panelist at 9th Annual Burrill Personalized Medicine Meeting
09/27/2013 Opexa to Present at the Aegis Capital Corp. 2013 Healthcare Conference
09/25/2013 Opexa Announces Conversion of all Convertible Secured Promissory Notes into Common Stock
09/05/2022 Opexa to Present at the Rodman & Renshaw 15th Annual Global Investment Conference
09/04/2022 Opexa Therapeutics, Inc. Announces Closing of Partial Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock
08/27/2013 Opexa Announces Issuance of 50th Patent for T-cell Immunotherapy Platform
08/14/2013 Opexa Therapeutics Reports Second Quarter 2013 Financial Results and Provides Corporate Update
08/13/2013 Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2013 Financial Results
08/13/2013 Opexa Therapeutics, Inc. Announces Closing of Public Offering of Common Stock
08/07/2022 Opexa Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
05/29/2013 Opexa Therapeutics Recognizes World MS Day and Will Present Poster With Secondary Progressive Multiple Sclerosis Data at CMSC / ACTRIMS Annual Meeting
05/28/2013 In Honor of World MS Day Opexa Therapeutics to Ring The NASDAQ Stock Market Closing Bell on May 28
05/14/2013 Opexa Therapeutics Reports First Quarter 2013 Financial Results and Provides Corporate Update
05/10/2021 Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2013 Financial Results
04/04/2022 Opexa Therapeutics to Present at the Regenerative Medicine - A Fundamental Shift in Science & Culture Conference
04/01/2022 Opexa Therapeutics Announces Changes to Senior Management Team
03/28/2013 Opexa Therapeutics Reports Year End 2012 Financial Results and Provides Corporate Update
03/04/2022 Opexa Therapeutics to Present at the 6th Annual European Life Science CEO Forum
02/07/2022 Opexa Therapeutics to Present at the 15th Annual BIO CEO & Investor Conference
02/07/2022 Opexa Therapeutics, Inc. Announces Pricing of Common Stock and Warrant Offering
02/05/2022 Merck Serono and Opexa Therapeutics Enter into Option and License Agreement for Development of Tcelna™ (imilecleucel-T) for Treatment of Multiple Sclerosis
01/23/2013 Opexa Therapeutics Closes Private Note Offering
01/15/2013 Opexa Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
© 2017 Opexa Therapeutics, Inc. All Rights Reserved.
Powered By Q4 Inc. 4.4.0.14